New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

A RECENT study has highlighted key biological and clinical factors linked to resistance to biologic therapies in patients ...

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

The favorable data provided support for two ongoing phase III, randomized, placebo-controlled trials of ESK-001 in moderate/severe plaque psoriasis. Two TYK2 inhibitors developed in China also ...

ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that drugs in this class might rival ...

The symptoms of psoriasis, a chronic inflammatory condition, can look different on people with differing skin tones. On lighter skin, plaque psoriasis can appear red; on darker skin, it can be ...

PSORIASIS is a chronic inflammatory skin disease influenced by both genetic and environmental factors, affecting ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.